Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
-
-
-
-
PR Newswire (Apr 1, 2013)
-
-
PR Newswire (Mar 27, 2013)
-
-
PR Newswire (Mar 12, 2013)
-
PR Newswire (Mar 4, 2013)
-
-
Stock Watch Tuesday, 26 February 2013VFC's Stock House • Tue, Feb 26
-
Weekly Stock Watch, Week Of 19 FebruaryVFC's Stock House • Tue, Feb 19
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
Trovagene's Foray Into The Conventions Of Molecular DiagnosticsJ. King • Thu, Nov 15, 2012 -
-
-
-
-
-
-
-
-
-
-
-
-
Stock Watch Tuesday, 26 February 2013VFC's Stock House • Tue, Feb 26
-
Weekly Stock Watch, Week Of 19 FebruaryVFC's Stock House • Tue, Feb 19
-
-
-
-
-
-
5 Biotech Winners From Last Week With High Short RatiosHeisenberg Principle • Mon, Dec 24, 2012 -
-
-
-
-
Stock Watch Wednesday, 12 DecemberVFC's Stock House • Wed, Dec 12, 2012
There are no Transcripts on TROV.
-
PR Newswire (Apr 1, 2013)
-
PR Newswire (Mar 27, 2013)
-
PR Newswire (Mar 12, 2013)
-
PR Newswire (Mar 4, 2013)
-
PR Newswire (Feb 12, 2013)
-
PR Newswire (Feb 6, 2013)
-
PR Newswire (Jan 3, 2013)
-
PR Newswire (Dec 20, 2012)
-
PR Newswire (Nov 28, 2012)
-
PR Newswire (Nov 19, 2012)
-
PR Newswire (Nov 14, 2012)
-
PR Newswire (Sep 13, 2012)
-
PR Newswire (Sep 4, 2012)
-
PR Newswire (Aug 29, 2012)
-
PR Newswire (Aug 15, 2012)
TROV vs. ETF Alternatives
Company Description
We are a development stage molecular diagnostic company that focuses on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring. Our novel tests predominantly use transrenal DNA, or Tr-DNA, and transrenal RNA, or Tr-RNA. Our primary focus is... More
